Skip to content

Net debt / EBITDA at other companies

IAR
Integra LifeSciencesIART
9.8×+6.2×
MiMedx Group logo
MiMedx GroupMDXG
-2.8×+98.8×
Bioventus logo
BioventusBVS
2.4×-17.0×
Artivion logo
ArtivionAORT
3.3×-4.9×
LeMaitre Vascular logo
LeMaitre VascularLMAT
-0.1×0.0×
Vericel logo
VericelVCEL
-0.5×-5.5×

Other financials

Income statement

See full
Revenue$37.2M-57.1%
Gross profit$63.0M-22.5%
Operating income-$68.9M-158%
Net income-$53.2M-182%
EPS (diluted)-$0.44-159%

Balance sheet

See full
Cash & equivalents$91.4M-16.9%
Total debt$39.4M+24.8%
Total equity$244.6M+0.7%
Total assets$520.0M+11.3%

Cash flow

See full
Operating cash flow$21.1M+206%
CapEx$3.1M-13.2%
Free cash flow$18.0M+176%

Valuation

See full
Market cap$312.68M-23.7%
Enterprise value$260.72M-21.3%
P/E115×
P/S0.6×-0.3×

Profitability

See full
Gross margin75.9%+0.8pp
Operating margin0.5%
Net margin0.5%+0.3pp
FCF margin6.9%

Returns & leverage

See full
Return on equity1.1%+0.6pp
Debt / equity0.2×0.0×
Current ratio3.5×-0.6×

Where this comes from

Calculated from Organogenesis Holdings Inc.’s reported figures.

Based on the most recent quarter.

The official record: Organogenesis Holdings Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organogenesis Holdings Inc.'s net debt / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organogenesis Holdings Inc.'s net debt / EBITDA?
Organogenesis Holdings Inc. (ORGO) reported net debt / EBITDA of -2.8× in Q1 2026.
What is the long-term trend for Organogenesis Holdings Inc.'s net debt / EBITDA?
Over 3 years (2020 to 2025), Organogenesis Holdings Inc.'s net debt / EBITDA has grown at a -43.4% compound annual growth rate (CAGR), from -0.2× to -0×.
What does net debt / EBITDA mean?
Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.